Payment overview · 2025
General Payments
$961.76
24 reported records · 9 companies
Healthcare provider profile · identity verified
Anwarul Islam, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHESAPEAKE, VA · NPI 1215948872
Verified facts
What the public records show
CMS Open Payments records show Anwarul Islam, MD received $961.76 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 54.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $524.22 | 54.5% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $131.55 | 13.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $103.87 | 10.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.16 | 6.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.17 | 4.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.33 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.37 | 2.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.49 | 2.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.60 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $961.76 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $262.54 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $232.84 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $114.20 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $103.87 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.16 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.17 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.82 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $29.33 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.84 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.37 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.37 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.37 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 299 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 62 |
| Carvedilol | Carvedilol | 243 | 54 |
| Methylprednisolone | Methylprednisolone | 230 | 91 |
| Losartan Potassium | Losartan Potassium | 202 | 42 |
| Potassium Chloride | Potassium Chloride | 188 | 43 |
| Metformin Hcl | Metformin Hcl | 169 | 39 |
| Bumetanide | Bumetanide | 167 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 160 | 27 |
| Meloxicam | Meloxicam | 148 | 43 |
| Omeprazole | Omeprazole | 145 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 28 |
| Terazosin Hcl | Terazosin Hcl | 135 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 34 |
| Lisinopril | Lisinopril | 116 | 28 |
| Furosemide | Furosemide | 115 | 28 |
| Jardiance | Empagliflozin | 115 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 28 |
| Allopurinol | Allopurinol | 98 | 21 |
| Simvastatin | Simvastatin | 98 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 17 |
| Eliquis | Apixaban | 82 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 15 |
| Risperidone | Risperidone | 77 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 74 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 16 |
| Spironolactone | Spironolactone | 65 | 16 |
| Glimepiride | Glimepiride | 63 | 13 |
| Trazodone Hcl | Trazodone Hcl | 60 | 12 |
| Atenolol | Atenolol | 58 | 13 |
| Azithromycin | Azithromycin | 54 | 46 |
| Alendronate Sodium | Alendronate Sodium | 52 | 13 |
| Gabapentin | Gabapentin | 46 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Methocarbamol | Methocarbamol | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Famotidine | Famotidine | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Haloperidol | Haloperidol | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 11 |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 11 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Klor-Con M20 | Potassium Chloride | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Niacin Er | Niacin | 22 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Clonidine | Clonidine | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Linzess | Linaclotide | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Desoximetasone | Desoximetasone | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Effer-K | Potassium Bicarbonate/Cit Ac | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $961.76 · 24 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, FARXIGA, JARDIANCE, LEQVIO, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, VIBERZI, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error